This report analyzes the worldwide markets for Bioterrorism in Millions of US$. The report provides separate comprehensive analytics for the US, Europe, Asia, and Middle East. Annual forecasts are provided for each region for the period of 2001 through 2015. The report profiles 66 companies including many key and niche players worldwide such as Acambis Plc., AVI BioPharma, Inc., Blücher Gmbh, Evogen, Inc., Human Genome Sciences Inc., ICX Technologies, Inc., ILC Dover LP, Medarex, Inc., Northrop Grumman Corporation, PharmAthene, Inc., Scott Health & Safety, Smiths Detection, The Baker Company, Universal Detection Technology and Universal Detection Technology.  Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

BIOTERRORISM              		MCP-1831
A GLOBAL STRATEGIC BUSINESS REPORT


                                            CONTENTS


  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-3
      Product Definitions and Scope of Study                            I-3


 II. EXECUTIVE SUMMARY

  1. INTRODUCTION                                                       II-1
      Current & Future Analysis                                         II-1
      Market Overview                                                   II-1

  2. UNDERSTANDING BIOTERRORISM                                         II-3
      A Brief Historic Account on Bioterrorism                          II-3
      Why Biological Agents?                                            II-4
      An Ideal Biological Weapon Candidate                              II-4
      Bioterrorism is Easy: The Myth!                                   II-4
      Biological Agents/Diseases with Potential for Biological Warfare  II-4
       Properties of Biological Agents with Potential for Use as
        Weapons of Mass Destruction                                     II-5
       Anthrax                                                          II-6
        The Anthrax History                                             II-6
        Types of Anthrax                                                II-7
         Inhalational Anthrax                                           II-7
         Cutaneous Anthrax                                              II-7
         Gastrointestinal Anthrax                                       II-7
        The Anthrax Symptoms, Treatment, and Vaccination                II-7
       Smallpox                                                         II-8
        The Smallpox History                                            II-8
       Plague                                                           II-9
        The Plague History                                              II-9
        Types of Plague                                                 II-9
         Bubonic Plague                                                 II-9
         Pneumonic Plague                                               II-10
       Botulism                                                         II-10
       Tularemia                                                        II-11
        The Tularemia History                                           II-12
       Viral Hemorrhagic Fevers                                         II-12
        Ebola Hemorrhagic Fever                                         II-12
        Marburg Hemorrhagic Fever                                       II-13
        Lassa Hemorrhagic Fever                                         II-13
       Q Fever                                                          II-14
       Brucellosis                                                      II-15
       Ricin                                                            II-16
       Others                                                           II-16

  3. MODES OF DELIVERY                                                  II-17
      Aerosol Dissemination                                             II-17
      Water Contamination                                               II-17
      Food Contamination                                                II-17
      Insect Vectors                                                    II-17
      Other                                                             II-18

  4. BIOTERRORISM DEFENSE PRODUCTS AND DETECTION EQUIPMENT              II-19
     DETECTION EQUIPMENT                                                II-19
       Point Detection Systems                                          II-19
       Standoff Detection Systems                                       II-19
       Passive Standoff Detection Systems                               II-19
      Defense Products                                                  II-19
       Vaccines                                                         II-19
       Personal Protective Equipment                                    II-20

  5. RECENT INDUSTRY ACTIVITY                                           II-21
      Sanofi Pasteur Acquires Acambis                                   II-21
      PharmAthene Acquires Avecia Biodefense Vaccines Business          II-21
      ICx Technologies Completes S3I Acquisition                        II-21
      Johnson & Johnson to Acquire Omrix                                II-22
      Emergent BioSolutions Enters into Joint Venture with Ninebio
       Sdn Bhd                                                          II-22
      Alert B&C, Frontline Robotics, and Dragon Securite Sign MoU       II-22
      Universal Detection and Kadinuo Sign Agreement                    II-23
      PharmAthene Signs Marketing Pact with Medison for Israeli Market  II-23
      PharmAthene Forms Alliance with Panacea Biotec                    II-23
      Innovative Biosensors and Universal Detection Plan Collaboration  II-24
      Acambis Wins Government Contract for ACAM2000™ Smallpox Vaccine   II-24
      Crucell, Integrated BioTherapeutics Win NIAID Funding for
       Vaccine Development                                              II-24
      Universal Detection Secures Repeat Order for Biodetection Kits    II-25
      Universal Detection Secures Repeat Order for Biodetection
       Training Equipment                                               II-25
      Universal Detection Secures and Completes Contract                II-25
      Hawaii Emergency Medical Services Orders Simulation and Bio-
       Detection Kits                                                   II-26
      IR BioSciences Raises Financing for Drug Development              II-26
      AVI BioPharma Files IND for Marburg                               II-26
      ICx Technologies Completes GHC Technologies Acquisition           II-26
      NanoSensors to Acquire DKL International                          II-27
      Allen-Vanguard to Acquire Hazard Management Solutions             II-27
      PharmAthene Announces Reverse Merger to Acquire Healthcare
       Acquisition                                                      II-27
      CytoGenix Enters into CRADA with USAMRIID                         II-28
      Advanced Life Sciences Announces Collaboration with NIAID         II-28
      U.S. BioDefense to Receive Exclusive License from Shine Holdings  II-28
      Emergent BioSolutions Signs Agreement to License VaxImmune        II-29
      Universal Detection Signs Distribution Agreement with ADVNT       II-29
      Universal Detection Secures Gulf Security Order for Detection
       Kits                                                             II-29
      Dycor Technologies Wins Rheinmetall Landsystems Contract          II-29
      AVI BioPharma Secures Bioterrorism Response Therapies Contracts   II-30
      Emergent BioSolutions Wins HHS Anthrax Biodefense Contract        II-30
      Nanotherapeutics Wins Anti-Bioterrorism Drug Contract from
       NIAID/ BARDA                                                     II-30
      SRI International Secures Contract for Anti-Biological Threat
       Drugs from DTRA                                                  II-31
      Universal Detection Completes Foot Locker Order for
       Bioterrorism Detection Kits                                      II-31
      PharmAthene Wins HHS Biodefense Contract                          II-31
      Ibis Biosciences Receives Four New Contracts from Government      II-32
      Universal Detection Receives Guaranteed Order from SSI            II-32
      Ichor Receives Navy Contract for Vaccine Development              II-32
      PharmAthene Receives Contract to Develop Anthrax Anti-Toxin       II-33
      General Dynamics Canada Secures Contract from Canadian Forces     II-33
      Universal Detection Commences R&D for Portable Anthrax Detector   II-34
      BioFactura Completes Initial Clinical Testing                     II-34

  6. PRODUCT LAUNCHES                                                   II-35
      Smiths Detection Introduces SmartBio™ Biological Agents Detector  II-35
      Safe Life Launches Triosyn Disposable Respirators                 II-35
      ICx Unveils Integrated System for CBR Threat Detection, SafeAir™  II-35
      Innovative Biosensors Unveils BioFlash Biological Detector        II-36
      Lawrence Laboratory Develops Biological, Chemical Agent
       Detection Machine                                                II-36

  7. FOCUS ON SELECT PLAYERS                                            II-37
      Acambis Plc (UK)                                                  II-37
      AVI BioPharma, Inc. (USA)                                         II-37
      Blücher Gmbh (Germany)                                            II-37
      Evogen, Inc. (USA)                                                II-37
      Human Genome Sciences Inc. (USA)                                  II-38
      ICX Technologies, Inc. (USA)                                      II-38
      ILC Dover LP (USA)                                                II-38
      Medarex, Inc. (USA)                                               II-39
      Northrop Grumman Corporation (USA)                                II-39
      PharmAthene, Inc. (USA)                                           II-39
      Scott Health & Safety (USA)                                       II-40
      Smiths Detection (USA)                                            II-40
      The Baker Company (USA)                                           II-40
      Universal Detection Technology (USA)                              II-41

  8. GLOBAL MARKET PERSPECTIVE                                          II-42
      Table 1: World Recent Past, Current & Future Analysis for
      Bioterrorism Detection Equipment by Geographic Region - US,
      Europe, Asia (Including Japan), and Middle East Markets
      Independently Analyzed with Annual Revenues in US$ Million for
      Years 2006 through 2015 (includes corresponding Graph/Chart)      II-42

      Table 2: World Historic Review for Bioterrorism Detection
      Equipment by Geographic Region - US, Europe, Asia (Including
      Japan), and Middle East Markets Independently Analyzed with
      Annual Revenues in US$ Million for Years 2001 through 2015
      (includes corresponding Graph/Chart)                              II-43

      Table 3: World 10-Year Perspective for Bioterrorism Detection
      Equipment Market by Geographic Region - Percentage Share
      Breakdown of Dollar Revenue for US, Europe, Asia (Including
      Japan), and Middle East Markets for Years 2006, 2009, and 2015
      (includes corresponding Graph/Chart)                              II-43


III. MARKET

  1. THE UNITED STATES                                                  III-1
      A.Market Analysis                                                 III-1
        A Case of Undue Importance                                      III-1
        Market Drivers                                                  III-2
        Market Dampers                                                  III-2
         Investment Bottlenecks                                         III-2
         Legislative Bottlenecks                                        III-2
        Government Biodefense Funding                                   III-3
         The Federal Biological Weapons Prevention and Defense Funding  III-3
          Table 4: The US Federal Government Spending on Bioweapons
          Prevention and Defense - Allocation of Funds in US$
          Million by Department/Agency from FY2001 to FY2007
          (includes corresponding Graph/Chart)                          III-4

          Table 5: The US Federal Government Spending on Bioweapons
          Prevention and Defense - Percentage Share Breakdown of
          Funds Allocation by Department/Agency for FY2001 and
          FY2007 (includes corresponding Graph/Chart)                   III-5

          Table 6: The US Federal Funding for the Department of
          Health and Human Services by its Constituent Agencies and
          Offices in US$ Million from FY2001-FY2007 (Including
          Requested Funding for the Year 2007) (includes
          corresponding Graph/Chart)                                    III-6
         The RDT&E Biodefense Funding                                   III-6
          Table 7: Biodefense Funding for Research, Development,
          Testing and Evaluation (RTD&E) by Agency/Department in US$
          Million from FY2001 to FY2007                                 III-7
         Biodefense Prevention Funding                                  III-8
          Table 8: Federal Biodefense Prevention Funding in US$
          Million from FY2001 to FY2007 (includes corresponding
          Graph/Chart)                                                  III-8
         Recent Awards for Biodefense Preparedness                      III-8
        Government Biodefense Initiatives                               III-9
         Project BioShield                                              III-9
         Pandemic and All-Hazards Preparedness Act                      III-10
         Public Health Security and Bioterrorism Preparedness and
          Response Act                                                  III-10
        Government Departments / Agencies                               III-10
         The Department of Health and Human Services                    III-10
          The National Institutes of Health                             III-11
          The Centers for Disease Control and Prevention                III-11
           The CDC Classification                                       III-11
           The CDC Regulated Shipment Agents                            III-13
         The Department of Defense                                      III-14
      B.Market Analytics                                                III-15
        Table 9: US Recent Past, Current & Future Analysis for
        Bioterrorism Detection Equipment Market - Annual Revenue in
        US$ Million for Years 2006 through 2015 (includes
        corresponding Graph/Chart)                                      III-15

        Table 10: US Historic Review for Bioterrorism Detection
        Equipment Market - Annual Revenue in US$ Million for Years
        2001 through 2005 (includes corresponding Graph/Chart)          III-15

        Table 11: US Recent Past, Current & Future Analysis for
        Bioterrorism Vaccines Market - Annual Revenue in US$ Million
        for Years 2006 through 2015 (includes corresponding
        Graph/Chart)                                                    III-16

        Table 12: US Historic Review for Bioterrorism Vaccines
        Market - Annual Revenue in US$ Million for Years 2001
        through 2005 (includes corresponding Graph/Chart)               III-16

  2. EUROPE                                                             III-17
       Market Analysis                                                  III-17
        Table 13: European Recent Past, Current & Future Analysis
        for Bioterrorism Detection Equipment Market - Annual Revenue
        in US$ Million for Years 2006 through 2015 (includes
        corresponding Graph/Chart)                                      III-17

        Table 14: European Historic Review for Bioterrorism
        Detection Equipment Market - Annual Revenue in US$ Million
        for Years 2001 through 2005 (includes corresponding
        Graph/Chart)                                                    III-18

  3. ASIA                                                               III-19
      A.Market Analysis                                                 III-19
        ASEAN and Canada Forge Ties to Combat Bioterrorism              III-19
        China Plans Counter-bioterrorism Security System                III-19
      B.Market Analytics                                                III-20
        Table 15: Asian Recent Past, Current & Future Analysis for
        Bioterrorism Detection Equipment Market - Annual Revenue in
        US$ Million for Years 2006 through 2015 (includes
        corresponding Graph/Chart)                                      III-20

        Table 16: Asian Historic Review for Bioterrorism Detection
        Equipment Market - Annual Revenue in US$ Million for Years
        2001 through 2005 (includes corresponding Graph/Chart)          III-20

  4. THE MIDDLE EAST                                                    III-21
       Market Analysis                                                  III-21
        Table 17: The Middle East Recent Past, Current & Future
        Analysis for Bioterrorism Detection Equipment Market -
        Annual Revenue in US$ Million for Years 2006 through 2015
        (includes corresponding Graph/Chart)                            III-21

        Table 18: The Middle East Historic Review for Bioterrorism
        Detection Equipment Market - Annual Revenue in US$ Million
        for Years 2001 through 2005 (includes corresponding
        Graph/Chart)                                                    III-22


 IV. COMPETITIVE LANDSCAPE

  Total Companies Profiled: 66 (including Divisions/Subsidiaries - 67)

  ------------------------------------------
  Region/Country                     Players
  ------------------------------------------
  The United States                    46 
  Canada                                4
  Europe                                9
     France                             4
     Germany                            1
     The United Kingdom                 1 
     Rest of Europe                     3
  Asia-Pacific (Excluding Japan)        4 
  Middle East                           4
  ------------------------------------------